• Something wrong with this record ?

Altered Expression of MBNL Family of Alternative Splicing Factors in Colorectal Cancer

N. Navvabi, P. Kolikova, P. Hosek, F. Zitricky, A. Navvabi, O. Vycital, J. Bruha, R. Palek, J. Rosendorf, V. Liska, P. Pitule

. 2021 ; 18 (3) : 295-306. [pub] -

Language English Country Greece

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22004378

BACKGROUND/AIM: Colorectal cancer is currently the third leading cause of cancer-related deaths and recently, alternative splicing has risen as its important regulator and potential treatment target. In the present study, we analyzed gene expression of the MBNL family of regulators of alternative splicing in various stages of colorectal cancer development, together with the MBNL-target splicing events in FOXP1 and EPB41L3 genes and tumor-related CD44 variants. MATERIALS AND METHODS: Samples of tumor tissue and non-malignant mucosa from 108 patients were collected. After RNA isolation and reverse transcription, the relative gene expression of a selected gene panel was tested by quantitative real-time PCR, followed by statistical analysis. RESULTS: MBNL expression was decreased in tumor tissue compared to non-tumor mucosa. In addition, lower expression was observed for the variants of FOXP1 and EPB41L3, while higher expression in tumor tissue was detected both for total CD44 and its cancer-related variants 3 and 6. Transcript levels of the MBNL genes were not found to be related to any of the studied clinicopathological characteristics. Multiple significant associations were identified in the target gene panel, including higher transcript levels of FOXP1 and CD44v3 in patients with distant metastases and connections between recurrence-free survival and altered levels of FOXP1 and CD44v3. CONCLUSION: Our results identified for the first-time deregulation of MBNL genes in colorectal cancer. Down-regulation of their transcripts in tumor tissue compared to matched non-tumor mucosa can lead to transition of alternative splicing patterns towards a less differentiated phenotype, which highlights the importance of alternative splicing regulation for tumor growth and propagation.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22004378
003      
CZ-PrNML
005      
20220127145313.0
007      
ta
008      
220113s2021 gr f 000 0|eng||
009      
AR
024    7_
$a 10.21873/cgp.20260 $2 doi
035    __
$a (PubMed)33893082
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Navvabi, Nazila $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
245    10
$a Altered Expression of MBNL Family of Alternative Splicing Factors in Colorectal Cancer / $c N. Navvabi, P. Kolikova, P. Hosek, F. Zitricky, A. Navvabi, O. Vycital, J. Bruha, R. Palek, J. Rosendorf, V. Liska, P. Pitule
520    9_
$a BACKGROUND/AIM: Colorectal cancer is currently the third leading cause of cancer-related deaths and recently, alternative splicing has risen as its important regulator and potential treatment target. In the present study, we analyzed gene expression of the MBNL family of regulators of alternative splicing in various stages of colorectal cancer development, together with the MBNL-target splicing events in FOXP1 and EPB41L3 genes and tumor-related CD44 variants. MATERIALS AND METHODS: Samples of tumor tissue and non-malignant mucosa from 108 patients were collected. After RNA isolation and reverse transcription, the relative gene expression of a selected gene panel was tested by quantitative real-time PCR, followed by statistical analysis. RESULTS: MBNL expression was decreased in tumor tissue compared to non-tumor mucosa. In addition, lower expression was observed for the variants of FOXP1 and EPB41L3, while higher expression in tumor tissue was detected both for total CD44 and its cancer-related variants 3 and 6. Transcript levels of the MBNL genes were not found to be related to any of the studied clinicopathological characteristics. Multiple significant associations were identified in the target gene panel, including higher transcript levels of FOXP1 and CD44v3 in patients with distant metastases and connections between recurrence-free survival and altered levels of FOXP1 and CD44v3. CONCLUSION: Our results identified for the first-time deregulation of MBNL genes in colorectal cancer. Down-regulation of their transcripts in tumor tissue compared to matched non-tumor mucosa can lead to transition of alternative splicing patterns towards a less differentiated phenotype, which highlights the importance of alternative splicing regulation for tumor growth and propagation.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a alternativní sestřih $7 D017398
650    _2
$a buněčná diferenciace $x fyziologie $7 D002454
650    _2
$a kolorektální nádory $x genetika $x metabolismus $x patologie $7 D015179
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a proteiny vázající RNA $x biosyntéza $x genetika $7 D016601
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kolikova, Pavla $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Hosek, Petr $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Zitricky, Frantisek $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Navvabi, Azita $u Biological Center, Faculty of Marine Sciences and Technologies in Bandar Abbas, Hormozgan University, Hormozgan, Iran
700    1_
$a Vycital, Ondrej $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic $u Department of Surgery, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Bruha, Jan $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic $u Department of Surgery, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Palek, Richard $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic $u Department of Surgery, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Rosendorf, Jachym $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic $u Department of Surgery, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Liska, Vaclav $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic $u Department of Surgery, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Pitule, Pavel $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic; pavel.pitule@lfp.cuni.cz $u Department of Histology and Embryology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
773    0_
$w MED00180194 $t Cancer genomics & proteomics $x 1790-6245 $g Roč. 18, č. 3 (2021), s. 295-306
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33893082 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127145309 $b ABA008
999    __
$a ok $b bmc $g 1751744 $s 1155527
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 18 $c 3 $d 295-306 $e - $i 1790-6245 $m Cancer genomics & proteomics $n Cancer Genomics Proteomics $x MED00180194
LZP    __
$a Pubmed-20220113

Find record

Citation metrics

Archiving options